PRA Health Sciences Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of PRA Health Sciences Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 16 Jul 2021 | Lorem |
| Mapi Pharma engages PRA Health Sciences as CRO for Phase III multiple sclerosis trial, CEO says | 19 Jan 2021 | Sean Rai-Roche |
| Veru welcomes CRO offers for Phase III trial in prostate cancer-linked hot flashes with decisions to be made promptly for June trial start, CEO says | 11 Feb 2020 | Reynald Castaneda |
| Immunomedics engages CRO PRA Health for Phase II sacituzumab trial in UC, exec says | 19 Mar 2019 | Reynald Castaneda |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer